Antibiotic Stewardship Program
A complete F-882 §483.80(a)(2) Antibiotic Stewardship Program policy plus survey-ready documentation tools for skilled nursing facilities. This template covers the protocols and systems required for antibiotic use review, the indication-and-duration documentation expectation, the pharmacist leadership role, the McGeer / Loeb surveillance criteria, the antibiotic use metrics that drive QAPI integration with F-880, and the surveyor-encounter workflow CMS uses during F-882 investigations.
F-882 is the second of the three F-tags in the CMS infection control cluster (F-880 IPCP, F-882 antibiotic stewardship, F-883 influenza and pneumococcal immunization). Under 42 CFR §483.80(a)(2), the facility's IPCP must include an antibiotic stewardship program that incorporates protocols to ensure appropriate antibiotic use, including protocols to obtain cultures and laboratory tests prior to antibiotic initiation when available, protocols to review antibiotic use and adjust as needed, and protocols to document indications, dose, route, duration, and response to therapy. Surveyors cite F-882 when antibiotic use is treated as a passive clinical decision rather than as a documented, reviewed, and adjusted clinical decision. The most common citation patterns include: antibiotic starts without documented indication, cultures not obtained prior to initiation when feasible, antibiotic continuation past clinical justification without documented reassessment, antibiotic use data not feeding back to the QAPI committee, no designated pharmacy leadership, and protocol content that exists on paper but is not operationalized in nursing or pharmacy workflow.
CMS guidance (State Operations Manual, Appendix PP, F-882) treats antibiotic stewardship as an outcome program, not a documentation program. The surveyor will pull the antibiotic use log, the indication-and-duration documentation for a sampled set of antibiotic starts, the pharmacist review and recommendation records, the culture-and-sensitivity turnaround documentation, and the QAPI committee minutes that show the program driving measurable change. Surveyors also pull the infection surveillance line list (forward-referenced to F-880) and correlate antibiotic use to infection events. Any break in the indication → culture → review → adjust → QAPI feedback chain is a citation trigger.
This template assumes that the consultant pharmacist serves as the antibiotic stewardship program lead and that the program operates as a substantive workflow integrated with the IPCP (F-880). The IP, the DON, the attending physicians, the unit nurse managers, and the QAPI committee each have roles defined by this policy. The consultant pharmacist retains professional accountability for clinical leadership of the program. The DON retains accountability for nursing workflow integration. The attending physicians retain professional accountability for the prescribing decisions that the program reviews. The Staff Development Coordinator retains accountability for in-service training on program elements for any new clinical staff. The included surveyor-encounter sheet should be walked at minimum 30 days before any anticipated survey window.
Purpose
The purpose of this policy is to establish a single, defensible, surveyor-reviewable antibiotic stewardship program under 42 CFR §483.80(a)(2) that operates as a substantive clinical workflow rather than as a documentation exercise. It defines program leadership, antibiotic use protocols, the indication-and-duration documentation expectation, the culture-and-laboratory pre-initiation expectation, the pharmacist review and recommendation cadence, the antibiotic use metrics tracked for QAPI, and the documentation chain required to demonstrate that the facility meets the regulatory requirement across the entire resident population.
Policy
The facility shall operate an antibiotic stewardship program as a documented component of the Infection Prevention and Control Program under 42 CFR §483.80(a)(1)–(2). The program shall be clinically led by the consultant pharmacist, with operational support from the Director of Nursing and the Infection Preventionist. The program shall establish and enforce protocols for antibiotic use including but not limited to: documented indication at initiation, culture and laboratory testing prior to initiation when available, dose and route documentation at initiation, defined expected duration at initiation, daily review of antibiotic continuation during the prescribing interval, pharmacist review of antibiotic use at minimum monthly, antibiotic use outcomes reported to the QAPI committee, and protocol content reviewed and updated at minimum annually. The program shall be integrated with the facility QAPI program under §483.75 and the IPCP under F-880.
Scope
This policy applies to all residents admitted to the facility who are started, continued, or discontinued on any systemic antibiotic for any indication, regardless of payer source or care setting within the facility. It applies to the consultant pharmacist serving as program lead, to the Director of Nursing and unit nurse managers integrating program protocols into nursing workflow, to the attending physicians prescribing and adjusting antibiotic therapy, to the Infection Preventionist integrating antibiotic use data with infection surveillance, to the Staff Development Coordinator running in-service training on program elements, and to the QAPI committee receiving and acting on program outcomes. It does not replace individualized clinical judgment by the attending physician in any resident-specific case.
Procedure
Indication and duration at initiation
Every antibiotic start shall be documented with the specific clinical indication (site, suspected pathogen, and clinical rationale), the dose, the route, the frequency, the planned start date, and a defined expected duration. Documentation shall be entered at the time of the order. A standing order for "antibiotic per indication" without a resident-specific rationale shall not meet the indication documentation expectation. The indication documentation shall be retained in the resident's medical record, in the antibiotic use log, and in the monthly pharmacy review documentation.
Culture and laboratory testing prior to initiation
The facility shall obtain appropriate cultures and laboratory tests prior to antibiotic initiation whenever feasible. Acceptable circumstances for deferring culture include: sterile site empiric therapy for life-threatening infection where any delay is clinically untenable, situations in which the resident is imminently transferring to acute care, and situations in which a culture has already been obtained within the prior 96 hours. The decision to defer culture shall be documented with the clinical rationale. Culture orders, results, and turnaround time shall be tracked as program metrics and reported to the QAPI committee.
Pharmacist review and recommendation
The consultant pharmacist shall conduct a documented antibiotic use review at minimum monthly. The review shall cover, at a minimum: every active antibiotic order in the facility, every new starts since the prior review, every culture result returned since the prior review, every antibiotic discontinued since the prior review with the reason, and any antibiotic continued past the originally documented expected duration. The pharmacist shall communicate any clinically significant antibiotic use concern to the attending physician and the DON in writing, with the recommendation documented.
Reassessment and duration adjustment
Antibiotic continuation past the originally defined expected duration shall trigger a documented reassessment by the attending physician. The reassessment shall include: review of clinical response, review of culture and laboratory data, documented rationale for continuation or change, and a new or confirmed end date. Reassessments that result in continuation shall be documented at minimum every 7 days for the duration of the antibiotic course, or more frequently when clinical indication warrants.
Documentation of response
Antibiotic response shall be documented in the resident's medical record at minimum daily for any resident on systemic antibiotics. Documentation shall include temperature curve, white blood cell count trend if obtained, clinical signs of infection response or progression, any culture or sensitivity update, and any antibiotic adjustment. Documentation of response shall be available to the consultant pharmacist for the monthly review and to the surveyor at the time of the request.
Operational elements
Antibiotic use metrics
The program shall track and report antibiotic use metrics at minimum monthly to the QAPI committee. Metrics shall include: new starts per 1,000 resident-days, defined daily doses (DDD) per 1,000 resident-days or an equivalent metric, percentage of new starts with documented indication, percentage of new starts with culture obtained prior to initiation, percentage of antibiotic courses continued past originally defined duration, and percentage of culture-positive cases where antibiotic was adjusted to match the sensitivity profile. Metrics shall be retained in the survey binder for the trailing 24 months.
McGeer and Loeb criteria use
Surveillance of healthcare-associated infections relevant to antibiotic decisions shall use the CDC NHSN long-term care definitions or McGeer criteria consistently. Diagnostic and therapeutic thresholds for suspected infection in the long-term care population shall reference Loeb criteria or comparable evidence-based guidance so that antibiotic initiation against asymptomatic bacteriuria, non-infectious cough, or non-specific functional decline is minimized. Thresholds shall be reviewed at minimum annually and shared with attending physicians at the QAPI committee.
QAPI feedback loop
Program outcomes shall be reviewed at the QAPI committee at minimum monthly. The committee shall review the antibiotic use metrics, identify trends, identify any case-level opportunity, recommend any program change, and document the change with a target completion date. At minimum one performance improvement project (PIP) annually shall be antibiotic stewardship related. The QAPI feedback loop shall be documented in committee minutes and the PIP documentation shall be retained in the survey binder.
Staff and prescriber education
The Staff Development Coordinator, in coordination with the consultant pharmacist and the IP, shall deliver in-service training on antibiotic stewardship program elements at minimum annually to all clinical staff, with additional in-service following any program change, any cited deficiency, or any observed gap. In-service attendance and content shall be documented in the training file.
Documentation
Documentation generated under this policy shall include: the antibiotic use log per month; the indication-and-duration documentation at each initiation; culture order and result records; the monthly pharmacist review and recommendation records; reassessment documentation at defined intervals; documentation of clinical response for each resident on systemic antibiotics; the antibiotic use metrics tables; the QAPI committee minutes referencing stewardship content; the annual PIP documentation; the program policy and procedure document; and the in-service training records. Documentation shall be retained per facility policy (commonly a minimum of one year for antibiotic use entries and indefinitely for the policy and PIP documentation) and shall be retrievable within surveyor timeframes.
Surveyor-encounter sheet
When the surveyor requests F-882 documentation, the facility shall produce, in order: (1) the antibiotic stewardship program policy; (2) the antibiotic use log for the trailing 12 months; (3) the indication-and-duration documentation for a sampled set of antibiotic starts, with corresponding culture orders and results; (4) the monthly pharmacist review and recommendation records; (5) the antibiotic use metrics tables and QAPI committee minutes that reference them; (6) the most recent annual PIP documentation; (7) the program policy cross-reference with the F-880 IPCP; (8) the in-service training records for clinical staff. The facility shall be ready to produce this documentation set within surveyor timeframes on Day 1 of survey.
Survey prep checklist
The consultant pharmacist and the DON shall complete a 30-day pre-survey F-882 audit covering: antibiotic use log currency for the trailing 12 months (≥ 90% of months with complete log); percentage of new starts with documented indication (target ≥ 95%); percentage of new starts with culture obtained prior to initiation (target ≥ 90% when feasible); percentage of antibiotic courses continued past defined duration with documented reassessment (target ≥ 95%); monthly pharmacist review currency; antibiotic use metrics currency for the trailing 12 months; QAPI committee minutes currency with stewardship content; annual PIP documentation currency; and in-service attendance currency for clinical staff. Audit findings and corrective action documentation shall be retained in the survey binder for the trailing 12 months.
References
Primary regulatory authority: 42 CFR §483.80(a)(2) — Infection Prevention and Control Program: antibiotic stewardship component. CMS State Operations Manual, Appendix PP — Guidance to Surveyors for Long Term Care Facilities, F-882 (forward-referenced to F-880 IPCP and QAPI §483.75). CDC Core Elements of Antibiotic Stewardship for Nursing Homes. SHEA / AMDA position statements on antibiotic stewardship in long-term care. Loeb criteria for initiating antibiotic therapy in long-term care populations. McGeer criteria for surveillance of healthcare-associated infection in long-term care. CDC NHSN long-term care facility surveillance definitions. Facility IPCP policy (F-880) and QAPI program plan.